We followed the COVID-19 pandemic in Manaus, one of the epicenters of COVID-19 in Brazil, using an epidemiological mathematical model and made five main conclusions. First, in early 2022, the actual cases exceed officially reported data by up to 8 times. Second, despite vaccination campaigns, the collective immunity threshold necessary was insufficient to contain severe cases of COVID-19. Next, the low observed mortality demonstrated the effectiveness of vaccination. Next, the drop in the vaccination rate combined with immune escape by the Omicron sub-variants (BA.2.12.1, BA.4, and BA.5) resulted in new wave after November 2022. Finally, to minimize severe cases of COVID-19, we need to raise vaccination thresholds above 90-95% of the entire population including children aged 6 months and older and require booster doses at least in four-month intervals. This approach would help to prevent severe cases of COVID-19 that cause hospitalizations and deaths.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1057/s41271-024-00530-0 | DOI Listing |
Pediatr Rheumatol Online J
December 2024
Translational Genetics Research Group, La Fe Health Research Institute (IIS La Fe), Avenida Fernando Abril Martorell nº 106 Tower A, 7th Floor, Valencia, Spain.
Background: Aicardi-Goutières Syndrome is a monogenic type 1 interferonopathy with infantile onset, characterized by a variable degree of neurological damage. Approximately 7% of Aicardi-Goutières Syndrome cases are caused by pathogenic variants in the ADAR gene and are classified as Aicardi-Goutières Syndrome type 6. Here, we present a new homozygous pathogenic variant in the ADAR gene.
View Article and Find Full Text PDFPediatr Rheumatol Online J
December 2024
Section of Rheumatology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Canada.
Background: Primary small vessel CNS vasculitis (sv-cPACNS) is a challenging inflammatory brain disease in children. Brain biopsy is mandatory to confirm the diagnosis. This study aims to develop and validate a histological scoring tool for diagnosing small vessel CNS vasculitis.
View Article and Find Full Text PDFAnn Vasc Surg
December 2024
Department of Vascular Surgery, IRCCS Sacro Cuore-Don Calabria, Negrar, VR, Italy.
Introduction: ProGlide is a suture-mediated vascular closure device (VCD) indicated for retrograde access closure at the common femoral artery (CFA). However, its off-label use for antegrade and/or superficial femoral artery (SFA) access has become common in many practices. This study evaluated the efficacy and safety of ProGlide for femoral artery access closure in patients undergoing antegrade infrainguinal endovascular procedures.
View Article and Find Full Text PDFAnn Vasc Surg
December 2024
Comparative Effectiveness and Clinical Outcomes Research Center, Riverside University Health System, Moreno Valley, CA, USA; Loma Linda University School of Medicine, Loma Linda, CA, USA. Electronic address:
Background: The management of patients with subclavian artery injury is rapidly evolving from an open to an endovascular approach. We aim to present an analysis of management and a comparison of outcomes according to the type of approach used to treat these challenging injuries.
Methods: Adult patients with subclavian arterial injuries were abstracted from the National Inpatient Sample database from 2012 to 2014 and 2016 to 2021.
J Allergy Clin Immunol Pract
December 2024
Servicio de Alergia, Hospital Clínico San Carlos, IdISSC, Madrid, Spain; Facultad de Medicina, Universidad Complutense, Madrid, Spain. Electronic address:
Background: Fish allergy affects children and adults worldwide and there are transient and persistent phenotypes.
Objective: We aimed to analyze persistence, severity and reactivity thresholds in challenge-confirmed fish allergic patients sensitized to parvalbumin.
Methods: Patients 12-65 years-old reporting immediate reactions to fish, with fish skin prick test ≥5 mm and IgE to cod and carp β-parvalbumins ≥0.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!